The term 'mood stabilizer' has been applied to a number of medications for the treatment of patients with bipolar disorder. The operational definition of the properties of a mood-stabilizing medication has varied according to the properties of specific medications and the clinical characteristics of the illness. Randomized controlled trials of agents accepted or proposed as mood stabilizers are reviewed to marshall the available evidence in support of this claim. In addition, potential pharmacological mechanisms underlying mood-stabilizing effects of established compounds are reviewed. Molecular Psychiatry (2002) 7, S8-S14.
Introduction
Bipolar disorder is a common, recurrent, often lifelong, major psychiatric disorder and a major public health problem. 1 This illness is characterized by recurrent manic, mixed and depressive episodes. These episodes, in turn, consist of disturbances in mood, thought, behavior and perception. 2 Without treatment, bipolar disorder is associated with substantial risks of morbidity and mortality. Data from a number of longterm outcome studies indicate that full recovery from discrete mood episodes often lags behind symptomatic improvement by many months. [3] [4] [5] Prognosis for full recovery from acute episodes also appears to be affected by the number of prior episodes, and recurrent episodes are associated with a risk of progressive deterioration in functioning. Response to at least one primary mood stabilizer, lithium, appears to be inversely related to the number of prior mood episodes a patient has experienced. 6 Bipolar disorder was the sixth leading cause of disability worldwide in 1990. 7 This illness can also be lethal. At least 25% of patients attempt suicide, and patients with mixed episodes display increased rates of suicidal ideation. 8, 9 These potentially devastating effects of bipolar disorder make early accurate diagnosis and thorough treatment essential. Since the introduction of lithium more than 50 years ago, pharmacological treatment has been the cornerstone of management of this illness. 10 Correspondence: Dr P Keck, Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 559, Cincinnati, OH 45267-0559, USA. E-mail: keckpeȰemail.uc.edu
Clinical treatment targets

The diagnostic criteria for mania and depression, as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR),
11 consist of symptoms reflecting disturbances in mood, thought, behavior and perception. Other symptoms of mania not listed in DSM-IV-TR include anxiety, hostility, impulsivity, violence, poor insight, confusion, memory impairment and sensory hyperacuity. 12 Collectively, these symptoms are the targets for pharmacological and psychotherapeutic interventions and require more diverse therapeutic actions than implied by the term 'mood stabilization' alone.
The stereotypical characterization of mania as a state of sustained euphoria and grandiosity applies to a minority of patients. Data from many phenomenological studies of the manic syndrome indicate that most patients experience irritability (80%), depressed mood (72%) and mood lability (69%), as often as euphoria (71%). 13 The predominance of specific mood states or their combination is determined in part by the severity of illness and comorbid psychiatric illnesses, such as alcohol-and substance-use disorders and anxiety disorders. 14 Cognitive dysfunction of varying degrees is common in mania and depression. Grandiosity (78%) and racing thoughts (71%) are common nonpsychotic cognitive disturbances in mania. 13 Impaired insight and lack of recognition of symptoms are also common in mania. 14 Inattention, indecisiveness and psychomotor retardation are common cognitive symptoms of depression.
Studies of the prevalence of behavioral symptoms of mania found that the most common manifestations were pressured speech (98%), logorrhea (89%), psychomotor agitation (87%), decreased need for sleep (81%), hypersexuality (57%) and extravagant behavior (55%). 13 Other, less frequent, symptoms included violence (49%), religiosity (39%), regression (28%) and catatonia (22%), which is more common in mood disorders than schizophrenia. 13 Although patients with bipolar depression often display symptoms indistinguishable from (unipolar) major depressive disorder, some studies suggest that atypical features of hypersomnia, hyperphagia and leaden paralysis may be more common in bipolar patients. 15 Psychotic or perceptual symptoms are a common complication of mania. In studies reviewed by Goodwin and Jamison, 13 at least two thirds of patients with bipolar disorder experienced psychosis during a mood episode, and in recent data from the Stanley Foundation Bipolar Network, more than 90% of patients reported experiencing psychotic symptoms during at least one mood episode (Keck PE et al, unpublished data) . All forms of psychosis, including hallucinations, delusions (mood-congruent and mood-incongruent; first-rank Schneiderian symptoms) and formal thought disorder, can occur during manic or mixed episodes. 16 The prevalence of psychosis in bipolar depression has been less extensively investigated, but may occur in up to one third of patients. 17 Because the acute affective episodes of bipolar disorder are characterized by this broad range of symptoms, primary mood-stabilizing agents would ideally have efficacy in treating multiple symptom domains.
Course of illness and relapse prevention
Bipolar disorder is a recurrent illness in more than 90% of patients who experience an index manic episode. 18 The prevention of mood episodes, eradication of interepisode subsyndromal symptoms and inhibition of the inherent cyclicity and mood lability that characterize the illness are the most important goals of long-term pharmacological management of bipolar disorder. Unfortunately, because of many methodological obstacles, randomized controlled trials of maintenance treatment in bipolar disorder have been difficult to execute. 19 Traditionally, mood-stabilizing medications, eg, lithium, divalproex and carbamazepine, have been antimanic agents. 20 However, efficacy in the treatment of acute mania does not necessarily imply that an agent will also have antidepressant or prophylactic efficacy. It is possible that an agent effective in preventing mood episodes could have limited to no efficacy in treating acute episodes. Such a medication with selective prophylactic benefit would address the core traits of bipolar disorder, its cyclicity and propensity for recurrence. To date, such an agent has yet to be identified.
Primary mood stabilizers
Although bipolar disorder is a heritable biological illness, its etiology and pathophysiology remain obscure.
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Thus, pharmacological treatment of bipolar disorder has been empirically based on the results of randomized controlled trials of agents observed by clinician-scientists to be therapeutic for various symptoms of the illness. Mood-stabilizing medications are effective in ameliorating symptoms of the illness, but cannot be said to restore normal homeostasis to the underlying biological mechanisms of the illness based on current understanding. Emerging data from neuroimaging and preclinical studies suggest that bipolar disorder may be associated with impairments of structural plasticity and cellular resilience. 21, 22 Over the years, the term 'mood stabilizer' has become synonymous with lithium's therapeutic effects: the amelioration of mood and psychotic symptoms during manic episodes and the prevention of subsequent mood episodes with maintenance treatment at therapeutic levels. 20 Substantial research efforts have been devoted to unraveling the mechanism(s) by which lithium exerts its mood-stabilizing actions. 21, 22 In parallel with basic research in lithium neuropharmacology, data from clinical studies revealed gaps in lithium's therapeutic effects. Patients with severe mania, 13 rapid cycling 23 and mixed episodes 24 have been reported to have lower response rates to lithium than patients without these clinical features. In addition to these limitations in lithium's efficacy, lithium is associated with a number of bothersome day-to-day side effects that limit its tolerability in a substantial minority of patients. 25 These limitations have spurred the development of pharmacological alternatives for patients intolerant or poorly responsive to lithium. However, for several decades following lithium's introduction, there was little progress in the development of other medications with mood-stabilizing properties. In recent years, a proliferation of new agents have been actively studies for their potential mood-stabilizing properties. 26 Divalproex was approved by the US Food and Drug Administration (FDA) in 1994 for the treatment of manic episodes associated with bipolar disorder. Olanzapine received similar approval in 2000. Divalproex and olanzapine expanded the therapeutic range of mood-stabilizing agents in having equal efficacy in manic and mixed episodes 24, 27 and acute efficacy in patients with rapid cycling. 27, 28 Data from randomized controlled trials indicate that divalproex and olanzapine effectively ameliorate behavioral, perceptual and cognitive symptoms in patients with acute manic or mixed episodes. 27, [29] [30] [31] [32] Recent data also indicate that, unlike typical antipsychotic agents, which exert antimanic effects but may also be depressogenic, olanzapine improved both manic and depressive symptoms compared with haloperidol. 32 There are currently no published data from randomized controlled trials regarding the efficacy of divalproex or olanzapine in the treatment of acute bipolar depression. Only indirect evidence is available to suggest that these agents may also have antidepressant effects in bipolar depression. 24, 27, [32] [33] [34] In one placebo-controlled randomized comparison of the efficacy of divalproex and lithium in the prevention of relapse into manic or depressive episodes, there was no significant difference in time to relapse among the three treatment groups. 35 In a secondary analysis, however, patients who began the trial on divalproex and were randomized to continue divalproex were significantly less likely to relapse than patients randomized to placebo. There are no published randomized controlled trials of olanzapine in the maintenance treatment of bipolar disorder. Data from open trials suggest that it may have efficacy in the long-term management of patients with bipolar disorder, 36,37 but these observations require confirmation in controlled studies.
Although data sufficient for an approved US FDA indication for treating any phase of bipolar disorder are lacking for carbamazepine, studies in acute mania, depression and prophylaxis suggest that this agent also has mood-stabilizing properties. 38 The efficacy of carbamazepine in the treatment of acute mania was superior to placebo in one crossover trial, 39 and comparable to lithium 40, 41 and chlorpromazine 42, 43 in comparison studies. Three small placebo-controlled studies found carbamazepine to have efficacy as monotherapy or in conjunction with lithium in patients with bipolar depression. [44] [45] [46] The efficacy of carbamazepine as a maintenance treatment has been less clearly substantiated. 47 Interpretation of the results of the only placebo-controlled trial is limited by the use of adjunctive antimanic and antidepressant medications for breakthrough symptoms during the trial. 48 Two comparison trials with lithium were recently completed. 49, 50 In the first study, patients receiving carbamazepine required significantly more adjunctive medications for breakthrough symptoms and experienced significantly more side effects leading to treatment discontinuation. 49 In the second trial, relapse rates were not significantly different between lithium-and carbamazepine-treated patients.
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Candidate agents
In the late 1980s and early 1990s, the thymoleptic properties of the prototypical atypical antipsychotic, clozapine, were first suggested to be mood stabilizing, and thus distinct from the specific antimanic activity of typical agents. 51 These observations have been based primarily on case reports and case series in highly treatment-refractory patients with bipolar disorder and the bipolar subtype of schizoaffective disorder. [51] [52] [53] [54] Two randomized controlled trials of clozapine treatment of patients with bipolar disorder have been published to date. 55, 56 One randomized controlled trial found comparable efficacy for clozapine and chlorpromazine in the treatment of hospitalized patients with acute bipolar mania. 55 The second randomized controlled trial compared the addition of clozapine vs treatment as usual in patients displaying manic symptoms with treatment-refractory bipolar or schizoaffective disorder. 56 In this long-term maintenance study, clozapine was superior to treatment as usual.
From these initial impressions of clozapine's apparent mood-stabilizing activity, as well as the evidence of olanzapine's efficacy in the treatment of manic and mixed episodes in patients with bipolar disorder, considerable interest has grown regarding the potential of other atypical antipsychotics as mood-stabilizing agents. To date, there are no controlled trials of any atypical antipsychotic in the acute treatment of bipolar depression, only preliminary observations from case series. 36, 37, [57] [58] [59] Similarly, there are no blinded controlled trials of these agents in the maintenance treatment of bipolar disorder. Risperidone was comparable in efficacy to haloperidol and lithium in a small 4-week comparison trial in hospitalized patients with acute bipolar mania. 60 This study had insufficient power to detect possible differences in efficacy among these agents. A second controlled trial of risperidone compared its efficacy with haloperidol and placebo as adjunctive treatment to lithium or divalproex. 61 Both antipsychotics produced significantly greater reductions in manic symptoms than placebo during the first 2 weeks of the trial. Ziprasidone has been studied in one large, multicenter, placebo-controlled trial in patients with acute bipolar mania. 62 In this study, ziprasidone was superior to placebo in reducing manic, psychotic, cognitive and behavioral symptoms. These findings confirmed earlier impressions of ziprasidone's thymoleptic effects from controlled trials in patients with schizoaffective disorder. 63 Data from controlled trials of quetiapine in bipolar disorder are not available. However, preliminary observations from case series suggest that this agent may also have antimanic 63, 64 and antidepressant effects in bipolar disorder. 65 New antiepileptic agents are also being actively studied as potential mood-stabilizing agents. Gabapentin, lamotrigine, oxcarbazepine and topiramate have been studied in randomized controlled trials in patients with bipolar disorder. Two studies assessed the efficacy of gabapentin in the treatment of affective symptoms. 66, 67 In both studies, the efficacy of gabapentin was not significantly different than placebo.
Lamotrigine has been studied in randomized controlled trials in all phases of bipolar disorder. Three studies assessed the efficacy of lamotrigine in the treatment of acute bipolar mania or hypomania. [67] [68] [69] The first study randomized patients with bipolar I and II disorders to lamotrigine, gabapentin or placebo in a crossover series of 6-week monotherapy trials. 67 There were no significant differences among the three treatment groups in reduction of manic symptoms. In the second trial, outpatients with manic, mixed or hypomanic symptoms who were inadequately responsive or intolerant to lithium at therapeutic dosages were randomized to receive lamotrigine or placebo for 8 weeks. 68 Lamotrigine or placebo were either added to ongoing lithium treatment or administered as monotherapy to patients unable to tolerate lithium side effects. There were no significant differences between lamotrigine and placebo in reduction of manic symptoms or response rate. In one other small inpatient trial, lamotrigine was comparable to lithium in reduction of acute manic symptoms. 69 However, these latter two trials had insufficient sample sizes to detect significant difference between treatment groups, and the lithiumcomparator study lacked a placebo group and used a low therapeutic lithium dosage of 800 mg day −1 . In contrast to these equivocal results in bipolar mania trials, lamotrigine was superior to placebo in a large, multicenter, placebo-controlled, parallel-group study as monotherapy in patients with acute bipolar depression. 70 In addition, there were no significant differences in the proportion of patients switching into manic or mixed episodes between the lamotrigine and placebo treatment groups. Finally, lamotrigine was compared with placebo in a maintenance relapse prevention study in outpatients with rapid cycling bipolar I and II disorders. 71 Lamotrigine was superior to placebo in time to need for supplemental medications and duration of time in the trial for bipolar II patients, but not bipolar I patients. These findings are consistent with the hypothesis that lamotrigine may have antidepressant, but no significant antimanic, effects in bipolar disorder. This profile has been used to propose an alternative definition of a mood stabilizer, a medication that effectively treats at least one aspect of bipolar disorder without exacerbating other phases of the illness. 20 Oxcarbazepine, an antiepileptic drug related to carbamazepine, has been studied in two active comparator trials in acute bipolar mania: one vs haloperidol 72 and one vs lithium. 73 There were no significant differences in efficacy among the treatment groups in these two trials. However, the studies lacked sufficient power to detect potential therapeutic difference, and neither contained a placebo control group. No studies, to our knowledge, have assessed the efficacy of oxcarbazepine in the treatment of bipolar depression. Two studies of oxcarbazepine maintenance treatment were too small to interpret. 74, 75 Topiramate has been studied in one randomized placebo-controlled trial in inpatients with acute bipolar mania. 76 An interim analysis of this study revealed efficacy trends for topiramate (at approximately 250 mg day −1 and 500 mg day −1 ) over placebo in reduction of manic symptoms. However, at the conclusion of the trial, there were no significant differences in efficacy in reduction of manic symptoms among the topiramate dosage groups and placebo.
Primary mood stabilizers and mechanisms of action
A number of pharmacological agents have been or are being studied as potential mood stabilizers. Data supporting efficacy in the treatment of different symptom domains of mania are greatest for lithium, divalproex, olanzapine, typical antipsychotics and ziprasidone. More modest evidence exists for carbamazepine, oxcarbazepine, risperidone and lamotrigine as antimanic agents. Mood stabilizers as antidepressants in acute bipolar depression have been much less studied. ComMolecular Psychiatry pelling data for efficacy in bipolar depression are only available for lithium and lamotrigine. Similarly, maintenance efficacy data from randomized controlled trials are only available for lithium, with more limited data for divalproex, carbamazepine and lamotrigine. These medications represent a diverse array of molecules with an even greater diversity of pharmacological mechanisms. Some common mechanisms may be shared among certain agents. For example, the atypical antipsychotics may exert antimanic effects via dopamine D 2 receptor antagonism and antidepressant activity by serotonin 5HT 2 receptor antagonism. [77] [78] [79] Although these proposed mechanisms may be overly simplistic, they represent real pharmacological differences between atypical and typical antipsychotics which, in turn, may reflect the unidirectional (antimanic) effects of typical agents compared with bidirectional (antimanic and antidepressant) effects of atypicals. The effects of proven and putative mood stabilizers on other neurotransmitter systems and receptors may also be relevant to their thymoleptic effects. Dysregulation of neurotransmission involving catecholamines, 80 acetylcholine, 81 serotonin, 82 GABA 83 and glutamate 84 have been implicated in the pathophysiology of bipolar disorder. Neuronal sensitization and kindling have also been proposed as possible pathophysiological mechanisms. 85 Recently, brain-derived neurotrophic factor has been shown to control dopamine D 3 receptor expression and to trigger behavioral sensitization by inducing overexpression of this receptor. 86 The effects of atypical antipsychotics on D 3 receptors could represent an unexplored mechanism contributing to their mood-stabilizing properties. 87 These or other receptor interactions may also simply represent the most overt and readily measurable pharmacological properties of atypical agents. The effects of the atypical antipsychotics and new antiepileptics on second messenger systems and cell survival pathways, including cAMP response element binding protein, brain-derived neurotrophic factor, Bcl-2 and mitogen activated protein kinases, have yet to be extensively studied. Some of these agents could exert moodstabilizing effects via these mechanisms. 21, 22, 88 Mood-stabilizing agents may also exert therapeutic effects via mechanisms that are only indirectly or peripherally related to the pathophysiology of bipolar disorder. Such effects could be additive or synergistic and raise the possibility that treatment with more than one agent, each exerting effects at different points along a pathophysiological process, might be more beneficial in acute and long-term treatment than treatment with one agent alone. This possibility has only recently been supported by preliminary acute treatment 61, 89 and maintenance studies.
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Conclusions
In recent years, rapid advances in basic and clinical neuroscience have yielded a number of potential primary mood-stabilizing medications and a promising means of exploring and understanding the mechanisms by which these agents may exert their therapeutic effects. As further advances ensue, so should the treatment, prognosis and quality of life of patients with bipolar disorder substantially improve.
